Results 121 to 130 of about 3,260 (169)

No increased risk of hepatic enzyme abnormalities with non-peptidic thrombopoietin receptor agonists in immune thrombocytopenia: A meta-analysis of randomized controlled trials. [PDF]

Exp Ther Med
Shen N, Wu R, Lu T, Liu S, Jiang Y, Yan J, Ning T, Dong C, Li J, Zhu S.   +9 more
europepmc   +1 more source

Real-world treatment patterns and outcomes among patients with immune thrombocytopenia (ITP) who switched treatment from eltrombopag or romiplostim to avatrombopag in the United States: Results from the REAL-AVA 3.5 study. [PDF]

Br J Haematol
Piatek C, Oladapo A, Kolodny S, Vredenburg M, Lucht S, Bland E, Pathak P, Feinberg B, Maitland H.   +8 more
europepmc   +1 more source

The association between immature platelet count and clinical characteristics in pediatric immune thrombocytopenia. [PDF]

Res Pract Thromb Haemost
Harris EM, Lambert MP, Grimes A, Despotovic J, Rothman JA, McComb C, Guedes B, Kirk S, Arulselvan A, Basara M, Cannon B, King S, Frelinger AL, Chen N, London WB, Grace RF.   +15 more
europepmc   +1 more source

MPL receptor dimerization and the thrombopoietin pathway in primary immune thrombocytopenia: from molecular mechanisms to targeted therapies. [PDF]

Front Med (Lausanne)
Wang Y, Liu C, Hu Y, Sun X, Zhang W, Zhu W.   +5 more
europepmc   +1 more source

Unintended First-Trimester Exposure to Two Distinct Thrombopoietin Receptor Agonists in Consecutive Pregnancies Without Maternal or Fetal Harm [PDF]

Turk J Haematol
Köseoğlu FD, Kum A.
europepmc   +1 more source

New thrombopoietin receptor agonist: avatrombopag

Japanese Journal of Thrombosis and Hemostasis
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

New benzimidazoles as thrombopoietin receptor agonists

Bioorganic and Medicinal Chemistry Letters, 2006
A novel benzimidazole series of small-molecule thrombopoietin receptor agonists has been discovered. Herein, we discuss the preliminary exploration of structure-activity relationships within this chemotype.
Richard M Keenan
exaly   +3 more sources

Thrombopoietin-receptor agonists

Current Opinion in Hematology, 2012
Thrombopoietin-receptor agonists (TPO-RAs) have been approved for use in immune thrombocytopenia (ITP) after showing safety and efficacy. There is increasing interest to expand the role of TPO-RAs, both in ITP as well as in other thrombocytopenic disorders.In ITP, more studies are providing evidence of TPO-RA efficacy and safety, as well as their ...
Paul A, Basciano, James B, Bussel
openaire   +2 more sources

Thrombopoietin Receptor Agonists: A Critical Review

Seminars in Hematology, 2015
Thrombopoietic agents have created a paradigm shift in the management of chronic or poorly responsive immune thrombocytopenia (ITP). There are ample randomized, placebo-controlled trial data, as well as long-term data gathered for more than 5 years; short-term efficacy and safety are well documented and long-term efficacy and safety data are emerging ...
William B, Mitchell, James B, Bussel
openaire   +2 more sources

Thrombopoietin-Receptor Agonists for Immune Thrombocytopenia

New England Journal of Medicine, 2011
To the Editor: In response to the review by Imbach and Crowther (Aug. 25 issue)1 of thrombopoietin-receptor agonists for primary immune thrombocytopenia: we would like to draw attention to the fact...
Jansen, Gerard, Swart, RM, te Boekhorst, Peter   +2 more
openaire   +3 more sources